A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).

Trial Profile

A Multicenter, Phase 2 Study Evaluating IMC-A12 in Combination With Sorafenib as First-Line Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Cixutumumab (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 17 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 02 Aug 2013 Planned end date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 12 Sep 2012 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top